Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/19/2012US20120183611 Oral pharmaceutical composition comprising diclofenac
07/19/2012US20120183610 glucocorticoid therapy
07/19/2012US20120183609 Modular systems for the controlled release of a substance with space and time control
07/19/2012US20120183608 Highly concentrated liquid acetaminophen solutions
07/19/2012US20120183607 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
07/19/2012US20120183606 Drug delivery system comprising polyoxazoline and a bioactive agent
07/19/2012US20120183605 Quinine formulations, method of making, and method of use thereof
07/19/2012US20120183604 Treatment of Triple Receptor Negative Breast Cancer
07/19/2012US20120183603 Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
07/19/2012US20120183602 Lipid formulation
07/19/2012US20120183600 Novel composition for treating metabolic syndrome and other conditions
07/19/2012US20120183596 Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes
07/19/2012US20120183595 Transdermal Pharmaceutical Delivery Composition
07/19/2012US20120183593 Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
07/19/2012US20120183591 Surfactant Mixtures for Improving the Deposition of Active Substances and for Reducing the Skin Irritant Action
07/19/2012US20120183589 Lipid Nanoparticles For Gene Therapy
07/19/2012US20120183587 Flavonol compositions
07/19/2012US20120183585 Gel based wound dressing and a method of synthesizing the same
07/19/2012US20120183581 Novel lipid formulations for nucleic acid delivery
07/19/2012US20120183579 Compounds for inflammation and immune-related uses
07/19/2012US20120183577 Compositions useful as inhibitors of protein kinases
07/19/2012US20120183576 Modified gram-negative bacteria for use as vaccines
07/19/2012US20120183568 Bioassay for the early detection of autoimmune diseases
07/19/2012US20120183564 Inhibition of endosomal toll-like receptor activation
07/19/2012US20120183563 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
07/19/2012US20120183554 Biomarker
07/19/2012US20120183553 Treatment and diagnosis of immune disorders
07/19/2012US20120183543 Diagnostic biomarkers for fibrotic disorders
07/19/2012US20120183538 Sparc antisense compositions and uses thereof
07/19/2012US20120183537 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer
07/19/2012US20120183535 use of inhibitors of bruton's tyrosine kinase (btk)
07/19/2012US20120183530 Stabilized immune modulatory rna (simra) compounds
07/19/2012US20120183527 Measurement of anti-amyloid antibodies in human blood
07/19/2012US20120183522 Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
07/19/2012US20120183521 Equine nutritional supplement
07/19/2012US20120183520 Minimally invasive methods for treating dysfunction of cardiac muscle
07/19/2012US20120183512 Tctex-1 regulatory sequence as stem cell marker
07/19/2012US20120183508 Gamma secretase inhibitor for treatment of herpesvirus infection
07/19/2012US20120183502 Combination therapy for lysosomal storage diseases
07/19/2012US20120183500 Articles and methods including stable thermally-responsive polymers
07/19/2012US20120183498 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
07/19/2012US20120183496 Inhibitors of hepatitis c virus polymerase
07/19/2012US20120183495 Avian colony stimulating factor 1 receptor binding proteins
07/19/2012US20120183493 Novel polymers
07/19/2012US20120183481 Heparanase activity inhibitor
07/19/2012US20120183476 Methods of administering liquid droplet aerosols of nanoparticulate drugs
07/19/2012US20120183472 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
07/19/2012US20120181230 Production of individual concentrate
07/19/2012US20120181201 Topical Formulation Containing a Tetracycline and a Method of Treating Skin Infections Using the Same
07/19/2012DE102011000207A1 N-Arylaminomethylenbenzothiophenone als Arzneimittel N-Arylaminomethylenbenzothiophenone as drugs
07/19/2012CA2860862A1 Methods and compositions for treating cancer and related methods
07/19/2012CA2824800A1 Oligosaccharide conjugates for targeting bacteria and uses related thereto
07/19/2012CA2824786A1 Substituted benzoazepines as toll-like receptor modulators
07/19/2012CA2824779A1 Substituted benzoazepines as toll-like receptor modulators
07/19/2012CA2824768A1 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
07/19/2012CA2824760A1 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
07/19/2012CA2824747A1 Novel glycosyltransferase gene and use thereof
07/19/2012CA2824743A1 Use of simalikalactone e as an anticancer agent
07/19/2012CA2824706A1 Pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration
07/19/2012CA2824516A1 Pyrimidine gyrase and topoisomerase iv inhibitors
07/19/2012CA2824493A1 Bace-2 inhibitors for the treatment of metabolic disorders
07/19/2012CA2824484A1 Implant comprising a core and a tube encasing the core
07/19/2012CA2824480A1 Anticancer therapy with dual aurora kinase / mek inhibitors
07/19/2012CA2824403A1 Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
07/19/2012CA2824401A1 Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
07/19/2012CA2824324A1 Mirna for treating diseases and conditions associated with neo-angiogenesis
07/19/2012CA2824293A1 5-(1,2,3-triazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives
07/19/2012CA2824220A1 Novel heterocyclic derivatives and their use in the treatment of neurological disorders
07/19/2012CA2824207A1 Crystalline oxazine derivative and its use as bace inhibitor
07/19/2012CA2824197A1 Processes for preparing isoquinolinones and solid forms of isoquinolinones
07/19/2012CA2824192A1 Lipid-lowering antidiabetic agent
07/19/2012CA2824175A1 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
07/19/2012CA2824113A1 Method for enhancing engraftment of haematopoetic stem cells
07/19/2012CA2824097A1 Oxazine derivatives and their use in the treatment of neurological disorders
07/19/2012CA2824096A1 Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
07/19/2012CA2824066A1 Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
07/19/2012CA2824050A1 Methods and drug products for treating alzheimer's disease
07/19/2012CA2824047A1 Heteroaryl compounds and methods of use thereof
07/19/2012CA2823972A1 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
07/19/2012CA2823913A1 Stem cell factor inhibitor
07/19/2012CA2823783A1 Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
07/19/2012CA2823655A1 Methods for treating prostatitis
07/19/2012CA2821985A1 Combination therapy
07/19/2012CA2821341A1 Compositions for anorectal use and methods for treating anorectal disorders
07/19/2012CA2818933A1 Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
07/19/2012CA2817757A1 Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
07/19/2012CA2815460A1 Process for preparation of phenyl carbamate derivatives
07/19/2012CA2814763A1 Compositions comprising enzyme-cleavable oxycodone prodrug
07/18/2012EP2476758A1 Method for prediction of therapeutic effect on chronic hepatitis c
07/18/2012EP2476756A1 Amine-containing lipids and uses thereof
07/18/2012EP2476706A2 Anti-MN antibodies and methods of using same
07/18/2012EP2476690A1 Compounds and pharmaceutical compositions for the treatment of viral infections
07/18/2012EP2476689A1 Thiocarbon-protecting groups for RNA synthesis
07/18/2012EP2476682A1 8-oxodihydropurine derivative
07/18/2012EP2476681A2 Amino-aza-adamantane derivatives and methods of use
07/18/2012EP2476680A1 (1-Azinone)-Substituted Pyridoindoles
07/18/2012EP2476679A2 Substituted triazoles useful as AXL inhibitors
07/18/2012EP2476678A1 Substituted carbonyl compounds
07/18/2012EP2476671A1 1H-Quinazoline-2,4-diones
07/18/2012EP2476670A1 Stable solid salts of ambrisentan
1 ... 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 ... 7860